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Abstract: Bone metastasis is a complex process that needs to be better understood in order to help
clinicians prevent and treat it. Xenografts using patient-derived material (PDX) rather than cancer
cell lines are a novel approach that guarantees more clinically realistic results. A primary culture
of bone metastasis derived from a 67-year-old patient with breast cancer was cultured and then
injected into zebrafish (ZF) embryos to study its metastatic potential. In vivo behavior and results of
gene expression analyses of the primary culture were compared with those of cancer cell lines with
different metastatic potential (MCF7 and MDA-MB-231). The MCF7 cell line, which has the same
hormonal receptor status as the bone metastasis primary culture, did not survive in the in vivo model.
Conversely, MDA-MB-231 disseminated and colonized different parts of the ZF, including caudal
hematopoietic tissues (CHT), revealing a migratory phenotype. Primary culture cells disseminated
and in later stages extravasated from the vessels, engrafting into ZF tissues and reaching the CHT.
Primary cell behavior reflected the clinical course of the patient’s medical history. Our results
underline the potential for using PDX models in bone metastasis research and outline new methods
for the clinical application of this in vivo model.
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1. Introduction
Metastasis from solid tumors is the main cause of cancer-related death [1]. It is a dynamic,
complex and multistep process involving tumor cell intravasation, spread to different organs,
extravasation and cancer cell colonization, and final outgrowth of secondary lesions [2]. Bone is the
most frequent site of cancer relapse after lung and liver and is one of the most common complications
in several primary tumors. In particular, 70% of patients with breast or prostate cancer relapse to bone
during the course of their disease [3–6]. The disease is usually not curable, and about 80% of patients
die within five years of the diagnosis of bone metastasis [3].
It was discovered in the late 19th century [7] that primary tumors have distinctive sites of
metastasis. Cancer cells that reach bone tissue may stop there and are capable of developing
into a secondary lesion through a process known as osteomimicry [1,8], i.e., cells acquire specific
features characteristic of bone resident cells which enable them to survive and proliferate in the new
microenvironment. For example, cancer cells, such as hematopoietic stem cells (HSCs), are capable
of expressing C-X-C motif chemokine receptor 4 (CXCR4) and thus take advantage of the same
physiological mechanism of chemoattraction used by HSCs. Cells expressing the same pattern of bone
cell integrins may remain in the blood endothelium and escape to bone parenchyma. When breast
cancer cells finally arrive in bone tissue, the balance between bone resorption and bone formation is
lost, usually in favor of bone resorption, with the consequent development of lytic or mixed lesions.
Osteoclast activity causes the release of growth factors from the bone matrix such as transforming
growth factor β (TGFβ), which contributes to cancer cell proliferation. Moreover, cancer cells in
the bone microenvironment are stimulated to produce cytokines and to secrete factors such as
interleukin 6 (IL6) and parathyroid hormone-related protein (PThrP), the latter inducing osteoblasts
to increase receptor activator of nuclear factor κB ligand (RANKL) and decrease osteoprogesterin
(OPG) production. The change of the RANKL/OPG ratio is one of the major causes of osteoclast
differentiation and activity. Briefly, these described relations constitute the backbone of a more complex
network of interactions between bone and cancer cells occurring in the bone after their arrival and
which are described as the “vicious cycle of bone metastases” [8].
The outstanding scientific findings of recent years have upgraded the role of the bone as one of
the most frequent sites of metastasis to that of a key actor and director in the different phases of the
entire metastatic process. Cancer cells induce the migration of vascular endothelial growth factor
receptor 1 (VEGFR1)-positive bone marrow-derived hematopoietic cells to sites of future metastasis
where they form cellular clusters preceding tumor cell arrival and increase fibronectin production and
matrix stiffness [9], creating a pre-metastatic niche in tissue [8]. It is worthy of note that cancer cells
can remain quiescent in bone marrow for several years until some stimuli determine their reactivation
with consequent spreading and formation of a secondary lesion to the bone, to other organs, or to the
site of the primary tumor [8,10].
One of the most widely used in vivo models to study cancer cell metastasis is that of xenografts
in immunodeficient mice. However, this model is hampered by being time-consuming and
labor-intensive. Zebrafish (Danio rerio) (ZF), a small freshwater tropical fish, and their transparent
embryos recently emerged as a promising xenograft tumor model [11–13]. ZF display distinct
features that facilitate the exploration of tumor development, angiogenesis, invasion and metastasis.
Moreover as a vertebrate, the ZF model shows high levels of physiologic and genetic similarities to
mammals, closely mimicking the clinical setting and permitting the natural history of the tumor to
be monitored. It is thus thought to be a potentially powerful model for preclinical studies on bone
metastases [13].
The majority of preclinical studies on bone metastases use commercially available immortalized
cancer cell lines or cancer cell lines selected in vivo to form metastases in bone tissue [14–17]. However,
cell lines, after being cultured in plastic supports and going through hundreds of freeze/thaw passages,
modify their phenotypic behavior in order to survive in the new microenvironment, which can seriously
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compromise results. Thus, the use of primary cultures obtained from tissue resected during surgery
could be the answer to overcoming these problems [13,18,19].
The present work focuses on the development of a patient-derived xenograft of a bone metastasis
in ZF embryos to study cell behavior during the metastatic process.
2. Results
2.1. Patient History
A 67-year-old female with breast cancer previously treated with surgery and systemic therapies
presented at our institute with bone and liver metastases. The patient was diagnosed with breast
cancer in 1999 and a left radical mastectomy was performed, revealing invasive ductal carcinoma G2,
pT1c (m), pN0, M0. ER 80% PgR 10%, Ki-67 20% and c-erbB2 0%. Adjuvant hormone therapy with
tamoxifen was administered. About 15 years later, the patient developed pain in her left arm and
an X-ray revealed the presence of an osteolytic lesion of about 60× 33 mm in the humerus, suggestive of
a secondary bone lesion. Magnetic resonance imaging (MRI) of the left shoulder confirmed the presence
of the bone lesion, together with an intra-articular fracture. A total body computed tomography (CT)
scan also revealed the presence of a liver lesion 67 × 62 mm in the fifth and sixth hepatic segments.
The α-fetoprotein value was normal. A total body bone scan showed a single area of pathological
uptake in the left humerus. Biopsy of the bone lesion confirmed the diagnosis of metastasis from ductal
carcinoma of the breast with mucinous aspects, estrogen receptor (ER) 100% progesteron receptor
(PgR) 70%, Ki-67 15% and c-erbB2 0%.
The multidisciplinary medical team examined the case and recommended surgery and hormone
treatment with anastrozole and bone-targeted therapy with zoledronic acid. The patient underwent
resection and prosthetic replacement of the humerus. Histology confirmed metastasis compatible with
breast cancer, ER 100% PgR 5%, Ki-67 5% and c-erbB2 0%. Surgical margins were negative (Figure 1).
The hepatic lesion was removed, histological analysis confirming metastasis of breast cancer origin
(ER 100%, Ki-67 20%, c-erbB2 0%).
There was no evidence of macroscopic disease at the most recent radiological evaluation (CT scan).
Treatment with anastrozole and zoledronic acid is ongoing and is well tolerated by the patient.
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Figure 1. Breast cancer bone metastasis. (A): (a) Histological hematoxylin and eosin (H & E) staining 
of bone metastasis (BM) primary culture (5× magnification). Mucinous areas show low cellularity; (b) 
H & E staining of BM primary culture (20× magnification). Monomorphic cells with round nucleus 
and nucleolus are seen in nests with a minor mucus quantity; (c) ER staining showing positivity; (B): 
Cytospin of BM primary cells. White arrows show pancytokeratin-positive cells. 
2.2. Breast Cancer Cell Lines 
The in vivo behavior of cells from a bone metastasis (BM) primary culture was compared with 
that of two different breast cancer cell lines: MCF7, a non-invasive, hormone receptor–positive line 
(like the BM primary culture), and MDA-MB 231, a highly invasive, triple-negative breast cancer line 
widely used for in vivo studies on breast cancer metastasis. MCF7 cells did not develop a phenotype 
Figure 1. Breast cancer bone metastasis. (A): (a) Histological hematoxylin and eosin (H & E) staining
of bone metastasis (BM) primary culture (5× magnification). Mucinous areas show low cellularity;
(b) H & E staining of BM primary culture (20× magnification). Monomorphic cells with round nucleus
and nucleolus are seen in nests with a minor mucus quanti y; (c) ER staining showing positivity;
(B): Cytospin of BM primary cells. White arrows show pancytokeratin-positive cells.
2.2. Breast Cancer Cell Lines
The in vivo behavior of cells from a bone metastasis (BM) primary culture was compared with
that of t o different breast canc r cell lines: MCF7, a non-invasive, hormone receptor–positive line
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(like the BM primary culture), and MDA-MB 231, a highly invasive, triple-negative breast cancer line
widely used for in vivo studies on breast cancer metastasis. MCF7 cells did not develop a phenotype
in the in vivo model and none survived the five-day duration of the experiment. Conversely,
MDA-MB-231 disseminated and colonized different parts of the zebrafish (ZF), including caudal
hematopoietic tissue (CHT), indicating a migratory phenotype (Figure 2).
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Figure 2. Representative image of MDA-MB-231 cell line five days after injection into the duct of
Couvier of 2 day post fertilization (dpf), Tg(fli1:GFP) ZF embryo. MDA-MB-231, labeled in red,
were monitored on a daily basis for the duration of the experiment (five days) and showed progressive
and extensive dissemination throughout the developing embryo (25× magnification).
2.3. Invasive Phenotype of Primary Culture of Bone Metastasis in Zebrafish Model
Positivity to pan-cytokeratin staining confirmed the presence of cancer cells in the primary culture.
In particular, a mean of 12% of cells per field was observed (20×magnification). Cells derived from the
primary culture and selected by colony picking, as reported in the Experimental Section, were injected
into the duct of Cuvier of 2 dpf Tg(kdrl:mCherry) ZF. The zebrafish model was used primarily to
stabilize the surgical material with an in vivo near-patient model and to assess the invasiveness of
the selected cancer cell population. It also enabled us to track migratory movements of injected cells
across the tissues of the developing zebrafish embryos at the single-cell level. Injected cells survived
and disseminated in the ZF embryos, extravasating and engrafting mainly in the perivascular milieu
of the CHT (Figure 3). The cells remained visible for the entire duration of the in vivo experiment.
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Figure 3. Images of carboxyfluorescein succinimidyl ester (CFSE)-labeled, patient-derived breast cancer
bone metastasis (primary cells) xenografted in Tg(kdrl:mcherry) ZF embryos. (A) Whole-body image
of the zebrafish embryo at 5 dpi (25× magnification). Primary cells disseminated predominantly in
the caudal hematopoietic tissues (CHT) of the embryo; (B) Details of (A), showing the interactions of
primary cells with the zebrafish vessels in the CHT. Cells extravasated in the CHT of the ZF embryo
and engrafted in cl se proxi ity of the v ssels. Fluoresc nt images merge with brightfield image,
63× mag ification; (C) Combined picture of the CHT of embryo in (A,B). Individual images were
taken at 63× magnification.
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2.4. Overexpression of Osteomimicry Markers by Primary Culture of Bone Metastasis
Several markers involved in breast cancer cell aggressiveness and osteomimicry were evaluated
in the BM primary culture and in the MCF7 and MDA-MB-231 cell lines. Secreted protein acidic and
rich in cysteine (SPARC) expression in the primary culture was almost 16,000-fold higher than that
of MCF7 cell lines and 2000-fold higher than that of MDA-MB-231. Integrin-binding sialoprotein
(IBSP), another osteomimicry marker, and matrix metalloprotease 9 (MMP9), a marker of cancer cell
aggressiveness expressed by osteoclasts in bone tissue, were also overexpressed in the BM primary
culture. Furthermore, higher levels of heparanase (HPSE), JAGGED1 (JAG1) and receptor activator of
nuclear factor κB (RANK) were observed in BM cells than in MCF7, a cell line with a hormone receptor
arrangement similar to that of the primary culture (Figure 4).
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configuration of gene expression analysis in BM primary culture and breast cancer cell lines; green/red
bars refer to high/low gene expression, respectively; black bars refer to intermediate levels of
expression; (B) Gene expression quantification by comparative threshold cycle (Ct) value method
(∆∆Ct). The primary culture was chosen as calibrator. See the Experimental Section for selected genes.
3. Discussion
Although the prognosis of patients with bone metastases from breast cancer is poor, in recent
years bone-targeted therapies used in combination with anticancer agents have substantially improved
quality of life and survival [8,20].
Numerous studies have used immunodeficient mice to develop human-to-mouse xenograft tumor
models to study the metastasis process and identify key steps and genes involved so that novel markers
and new targets for the development of innovative drugs can be derived [8,14,16].
Current experimental procedures have limitations because of the length of time it takes for
tumors to grow and spread, the variation in the tumor growth rate in vivo, and the high costs of
breeding and housing large numbers of mice. The ZF model has a number of important advantages
over traditional mouse models, i.e., simplicity of genetic manipulation, inexpensive housing,
rapid embryonic development, and easy visualization of internal structures. Furthermore, as fish
produce 100–200 eggs/mating, in vivo experiments are designed with a higher number of replicates
than those of mice models, leading to a higher statistical power and opening up new possibilities for
detecting rare phenotypes. Some studies have shown that human tumor cells proliferate and interact
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with vessel tissues in ZF embryos without the risk of rejection as the latter are devoid of a mature
immune system [21–24]. ZF models have thus become a valid alternative for overcoming mice model
limitations, e.g., when a high number of cells need to be injected. The majority of studies on the
metastasis process take advantage of commercially available immortalized cancer cell lines [14–17]
which, in adapting to their new environment, tend to lose cell heterogeneity and compensate for the
loss of stromal contribution. During the process of adaptation, clones with a higher proliferative
rate than that of the primary tumor and thus not representative of the cancer cell population may be
selected [13]. Surgical material would perhaps be more suitable to develop patient-derived xenografts
in which the stromal counterpart and cancer cell heterogeneity are both preserved.
However, as the quantity of material available is often insufficient for use in murine models,
the ZF becomes the perfect candidates to substitute mice models. As such, 100–200 replicates can
be performed with as few as 400–500,000 cells, providing high reproducibility and robust results.
Some researchers have developed PDXs in ZF models to study human cancer cell behavior, including
response to therapy [18,19,25,26]. The ZF has also shown to be a suitable model to study metastases
as cancer cells with different in vitro invasive potential preserve this behavior after injection into ZF
embryos [26].
The current study focused on the development of a PDX from a breast cancer bone metastasis
in ZF embryos. We first validated this in vivo model by testing the ability of two well-established
breast cancer cell lines to colonize the CHT of two-day post-fertilization (dpf) ZF embryos. We used
a red dye, CM-DiI dye, commonly used in this model, to label the cell lines. One disadvantage
of this dye is that, after injection into the ZF embryos, labeled cells frequently produce debris and
apoptotic bodies at later time points, lowering the signal-to-noise ratio and thus hampering the correct
quantification of the phenotype. We therefore set up a labeling strategy based on the green dye
carboxyfluorescein succinimidyl ester (CFSE) to obtain a clearer phenotype for the injection of the
primary bone metastasis culture.
The hormone receptor–positive MCF7 cell line did not colonize the CHT efficiently, whereas the
highly aggressive and triple-negative cell line MDA-MB-231 showed efficient and widespread
colonization of the ZF embryo including the CHT. A comparison between the grafting potential
of the patient-derived bone metastasis and that of the two breast cancer cell lines enabled us to
evaluate whether the detected phenotype of the patient-derived cells could be ascribed to the common
tissue of origin of the cells. Despite the histological and molecular similarities, i.e., tissue of origin
and hormone receptor pattern of MCF7 cells, respectively, the patient-derived cells showed a specific
grafting pattern with cells mainly colonizing the CHT of the ZF, suggesting that the in vivo behavior
of these cells may be due to an adaptation process to the bone tissue of the patient. As the CHT is the
first homing and expansion site for hematopoietic stem cells in the ZF embryo [27], the experimental
phenotype can be considered as an expression of bone marrow tropism [28]. A more detailed and
mechanistic description of the process of dissemination and colonization of the CHT by cancer cells
can be found in the study by He et al. [29].
This technique produced an aspecific signal detectable in the intestinal tract of the zebrafish due
to dye leakage at early time points, but provided a crisp fluorescent signal at later time points.
Although the hormone receptor–positive MCF7 cell line did not efficiently colonize the CHT,
the highly aggressive and triple-negative cell line MDA-MB-231 showed efficient widespread CHT
colonization and local growth. We then assayed cells collected from a lytic bone lesion of a patient
with metastatic hormone receptor–positive breast cancer and showed, for the first time in this model,
engraftment and local growth of the ex vivo cells. Furthermore, cells colonized different parts of
the embryos, showing an aggressive phenotype. As the CHT is the primary hematopoietic organ
of the zebrafish, the experimental phenotype can be considered as an expression of bone tropism.
Although the primary culture had the same hormonal receptor pattern as that of MCF7, its behavior
differed substantially as MCF7 cells did not show a phenotype in vivo, as previously reported.
The phenotype of the primary culture resembled that of the invasive cell line MDA-MB-231. Our in vivo
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results appear to reflect the patient’s clinical history; cells were initially quiescent and then re-activated,
going on to develop concurrent bone and hepatic lesions. Fifteen years after the primary diagnosis of
breast cancer, the patient developed bone and hepatic disease, both as single metastatic localizations.
The presence of visceral disease is suggestive of a different and more aggressive phenotype than that
of the indolent primary tumor.
We also studied the gene expression profile of the breast cancer cell lines and the primary
culture for markers of osteomimicry and aggressiveness. As the primary cell population was
heterogeneous, its gene expression profile was not ascribable to either of the two cancer cell lines.
Of note, SPARC expression was higher in the BM primary culture than in MCF7 and MDA-MB-231.
This protein, also known as osteonectin, is normally expressed by resident bone cells and overexpressed
by cancer cells in osteomimicry [30]. It is also thought to play a role in the chemoattraction of both
breast and prostate cancer cells [31] and has been proposed as a biomarker for bone metastasis [32].
As SPARC is expressed by normal bone cells, it was no surprise to find high levels of it in the bone
metastasis primary culture. The primary culture also overexpressed other markers (Jagged1 and
RANK) [33–36].
4. Experimental Section
4.1. Cell Cultures
The experiments were performed on MDA-MB-231, a triple-negative human breast cancer cell
line, and on MCF7, a hormone receptor–positive breast cancer cell line, both obtained from the America
Type Culture Collection (Rockville, MD, USA). Cells were cultured as a monolayer in 75-cm2 flasks
at 37 ◦C in Dulbecco’s Modified Eagle’s medium (DMEM) medium (PAA, Piscataway, NJ, USA)
supplemented with 10% fetal bovine serum and 1% glutamine (PAA) and 10% penicillin/streptomycin
in a 5% CO2 atmosphere. Cells were cultured until they reached 90%–100% confluence and then
supplemented with fresh DMEM medium, which was collected after 24 h, filtered through a 0.22 µm
filter, aliquoted and stored at −20 ◦C.
4.2. Isolation of Primary Bone Metastasis Cells
The bone tumor specimen was obtained from a bone metastasis resected from the left humerus of
a 67-year-old woman with a previous history of breast cancer. The protocol IRST B039 was reviewed
and approved by the ethics Committee IRST IRCCS AVR and by the Medical Scientific Committee of
IRST in February 2015. The study was performed in accordance with the principles of Good Clinical
Practice and the Helsinki Declaration. The patient gave written informed consent to take part in
the study.
The surgical material was analyzed and selected by an experienced pathologist and processed
within 3 h of removal. The specimen was washed twice in sterile phosphate buffered saline (PBS)
supplemented with 10% penicillin/streptomycin and disaggregated into 1–2 mm3 pieces with sterile
surgical blades. The obtained fragments were incubated with 2 mg/mL collagenase type I (Millipore
Corporation, Billerica, MA, USA) at 37 ◦C under stirring conditions. The enzymatic digestion was
stopped after 2 h by adding complete DMEM medium. The cell suspension was then filtered with
100 µm sterile Filters (CellTrics, Partec, Münster, Germany). Cells were counted and cultured at
a density of 80,000 cells/cm2 in standard monolayer cultures. All cells were maintained in complete
DMEM medium at 37 ◦C in a 5% CO2 atmosphere.
After a seven-day culture, a colony of cells that morphologically resembled cancer cells was
selected with a plastic ring (Sigma, St. Luois, MO, USA), trypsinized and reseeded in a different well.
The obtained cell population was expanded through a further three to four passages so that it could be
used for subsequent experiments.
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4.3. Immunocytochemistry
The primary culture suspension was counted and cytocentrifuged for 8 min at 900 rpm onto glass
slides at a concentration of 2 × 105 cells/spot. The cytospin preparations were fixed in acetone and
chloroform, air-dried overnight and stored at −20 ◦C. Immunostaining to detect CK-positive cells was
performed with the Epimet® kit (Micromet, Deutschland GmbH, Düsseldorf, Germany) which uses
the monoclonal antibody A45-B/B3, a pancytokeratin marker.
4.4. Prepapration of Cells for Implantation into Zebrafish (ZF) Embryos
MDA-MB-231 and MCF7 cell lines and the primary culture were gently washed with PBS and
harvested with trypsin, counted and resuspended at a density of 106/mL. The breast cancer cell lines
were stained with CMDiI dye (Sigma), while the primary culture was stained with CellTrace™ CFSE
Cell Proliferation Kit (Life Technologies, Carlsbad, CA, USA), in accordance with the manufacturers’
instructions. Each labeled cell suspension was loaded into borosilicate glass capillary needles (1 mm
outer diameter × 0.78 mm inner diameter; Harvard Apparatus, Saint-Laurent, QC, Canada) and
injected within 3 h of cell harvest.
4.5. In Vivo Experiments with the ZF Model
The ZF transgenic lines Tg(kdrl:mCherry) and Tg(fli1:GFP) were used for the in vivo studies of
the breast cancer cell lines and primary culture, respectively. Zebrafish and embryos were raised,
staged and maintained according to standard procedures in compliance with the local animal welfare
regulations and the EU Animal Protection Directive 2010/63/EU. N-phenylthiourea 0.2 mM (Sigma)
was applied to prevent pigment formation from the first dpf.
Two-dpf ZF embryos were anesthetized with 0.003% tricaine (Sigma) and positioned on a 10 cm
petri dish coated with 1% agarose. Then 50–400 manually counted cells were injected into the
duct of Cuvier using a Pneumatic Pico pump and a micromanipulator (WPI, Sarasota, FL, USA).
After implantation with cancer cells, the ZF embryos (including non-implanted controls) were
maintained at 34 ◦C as a compromise between the optimal temperature requirements for fish and
mammalian cells [24]. Up to 400 implantations were manually achieved per h, with survival rates of
>80% up to the 6th dpi. Fluorescent image acquisition was performed using a Leica MZ16FA stereo
microscope (Leica Microsystems GmbH, Wetzlar, Germany). Separate images of the various segments
of the ZF embryos were blended together to form a composite image using Adobe Photoshop CS6
software (Adobe Systems, Mountainview, CA, USA).
4.6. Quantitative Real-Time PCR (qPCR)
Total mRNA of the primary culture and cancer cell lines was isolated using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. Five hundred nanograms
of RNA were reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad, Hercules, CA, USA).
Real-Time PCR was performed on the 7500 Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA) using the TaqMan gene expression assay mix (Applied Biosystems). Amplification was
performed in a final volume of 20 µL containing 2× Universal master Mix (Applied Biosystems),
2 µL of cDNA in a total volume of 20 µL. The following markers were analyzed: OPG, JAG1, CXCR4,
RANK, IBSP, TFF1, SPARC, HPSE, CTGF, MMP-9, LOX and CDH1. The stably expressed endogenous
β-actin and HPRT and were used as reference genes. The amount of transcripts was normalized
to the endogenous reference genes and expressed as n-fold mRNA levels relative to a calibrator
using a comparative threshold cycle (Ct) value method (∆∆Ct). RNA extracted from MCF7 cell
line was used as calibrator. Gene expression analyses were graphed by heatmap using R software
(https://www.R-project.org/).
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5. Conclusions
Finally, we propose an original approach to study the metastatic process and cancer cell
aggressiveness comprising the use of patient-derived primary cultures in the in vivo ZF model.
The primary culture in the ZF showed behavior resembling that of the patient’s medical history
but differing from that of the cancer cell line sharing the same hormonal receptor status and could thus
be used to better understand drug sensitivity and to identify both prognostic markers and markers
that are predictive of response to therapy. These results highlight the importance of using near-patient
models in bone metastasis research and outline new methods for the clinical implementation of this
in vivo model.
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Abbreviations
BM bone metastasis
CDH1 cadherin-1
CHT caudal hematopoietic tissues
CTGF connective tissue growth factor
CXCR4 C-X-C chemokine receptor type 4
dpf days post fertilization
HSCs hematopoietic stem cells
HPSE heparanase
HPRT hypoxanthine phosphoribosyltransferase 1
IBSP integrin binding sialoprotein
IL6 interleukin 6
LOX lysyl oxidase
MMP-9 matrix metallopeptidase 9
JAG1 jagged1
OPG osteoprotegerin
PBS phosphate buffered saline
PDX patient-derived material
PThrP parathyroid hormone-related protein
RANK receptor activator of nuclear factor κB
RANKL receptor activator of nuclear factor κB ligand
TGFβ transforming growth factor β
SPARC secreted protein acidic and cysteine rich
TFF1 trefoil factor 1
Ct threshold cycle
VEGFR1 vascular endothelial growth factor receptor 1
ZF Zebrafish
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